Eye Know O.D. logo
Register
Email Address: *
First Name: *
Last Name: *
Title:
Profession:
Password: *
Confirm Password: *

By clicking “Register” you are agreeing to the Terms and Conditions and Privacy Policy.

Cosopt PF®

Dorzolamide HCL 2% / Timolol Maleate 0.5%
ophthalmic solution
Antiglaucoma
[ Carbonic Anhydrase Inhibitor, Beta Blocker]
Indication

Indication

Reduction of elevated IOP in open-angle glaucoma or ocular hypertension
Mechanism of Action

Mechanism of Action

Combines dorzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker. Dorzolamide inhibits carbonic anhydrase in the ciliary processes, decreasing aqueous humor production, while timolol reduces aqueous formation by blocking beta2 receptors on nonpigmented ciliary epithelium, thereby reducing intraocular pressure
Common quantities available

Available Quantities

60ct 0.2 ml vials, 180 ct 0.2 ml vials
Dosage

Dosage/Instructions

1 drop in the affected eye(s) twice daily, 12 hours apart
Pregnancy & Nursing Data

Pregnancy & Nursing

Use cautiously during pregnancy; no adequate and well-controlled studies in pregnant women
Pediatric Use

Pediatric Use

≥2 years
Warnings Tab

Contraindications, side effects, etc.

Contraindicated in patients with bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock, and hypersensitivity to any component. Warnings include potentiation of respiratory reactions including asthma, cardiac failure, sulfonamide hypersensitivity, obstructive pulmonary disease, increased reactivity to allergens, potentiation of muscle weakness, masking of hypoglycemic symptoms in diabetic patients, masking of thyrotoxicosis, renal and hepatic impairment, impairment of beta-adrenergically mediated reflexes during surgery, and potential for corneal endothelium damage. Adverse reactions include taste perversion, ocular burning/stinging, conjunctival hyperemia, blurred vision, superficial punctate keratitis, eye itching, and less commonly, gastrointestinal disturbances, drowsiness, confusion, and systemic effects due to beta-blockade.